Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM8C1H4)

• Drug Name: PF-06823859 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Dermatomycosis	EA60	Phase 2	[1]
Rheumatoid arthritis	FA20	Phase 2	[2]
Lupus	4A40	Phase 1	[3]

• Cross-matching ID: TTD Drug ID: DM8C1H4

Molecule-Related Drug Atlas

Drug(s) Targeting Interferon-beta (IFNB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PEGylated IFN beta 1-a	DMRH0D5	Type-2 diabetes	5A11	Approved	[4]
PLEGRIDY	DMAKXW9	Multiple sclerosis	8A40	Approved	[5]
Interferon beta-1a	DM1A6RV	Multiple sclerosis	8A40	Approved	[6]
FP-1201	DM823WQ	Acute lung injury	NB32.3	Phase 3	[7]
NU-100	DMA16IL	Multiple sclerosis	8A40	Phase 3	[8]
Biferonex	DM57B9J	Multiple sclerosis	8A40	Phase 3	[9]
AZ-01, PEGylated interferon-beta	DMHFUJT	Multiple sclerosis	8A40	Phase 2	[8]
Interferon beta 1a	DMQSA7H	Discovery agent	N.A.	Phase 2	[10]
ARX-424	DM4CZ2Y	Multiple sclerosis	8A40	Phase 1	[8]
Gene therapy, IFN-b	DMJP83V	Glioblastoma multiforme	2A00.0	Phase 1	[11]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Interferon-beta (IFNB1)	TT4TZ8J	IFNB_HUMAN	Blocker	[2]

References

• [1] ClinicalTrials.gov (NCT03181893) A Study In Adults With Moderate To Severe Dermatomyositis. U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol. 2014 Jul;13(7):657-65.
• [5] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [6] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [7] The effect of intravenous interferon-beta-1a (FP-1201) on lung CD73 expression and on acute respiratory distress syndrome mortality: an open-label study.Lancet Respir Med. 2014 Feb;2(2):98-107.
• [8] PEGylated interferon beta-1a in the treatment of multiple sclerosis - an update. Biologics. 2013; 7: 131-138.
• [9] Improving compliance with interferon-beta therapy in patients with multiple sclerosis. CNS Drugs. 2009;23(6):453-62.
• [10] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [11] Interferon-beta gene therapy for cancer: basic research to clinical application. Cancer Sci. 2004 Nov;95(11):858-65.